CPRX

We rate CATALYST PHARMACEUTICALS, INC. (CPRX) as a Hold with a composite score of 63.5/100 at a current price of $23.73. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.

The rating is primarily driven by strength in value (85th percentile) and stability (82th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (38th percentile) and momentum (52th percentile) tempers our overall conviction. We assign a Narrow Moat rating (55/100), Low uncertainty, and Exemplary capital allocation.

Key items to watch: sustainability of the current growth rate. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is widening, which provides additional comfort in the durability of the competitive position.

CATALYST PHARMACEUTICALS, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 63.5/100 places it at rank #387 in our full 7,333-stock universe. At $2.4B in market capitalization, CATALYST PHARMACEUTICALS, INC. is a mid-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.

Revenue is growing at 21%, though momentum at the 52th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.

The margin cascade tells an important story: gross margins of 86% (+43.3pp vs sector) narrow to operating margins of 44% (+42.3pp vs sector) and net margins of 36.3%, yielding a gross-to-net conversion rate of 42%. This efficient conversion suggests well-controlled operating costs and limited margin leakage between the gross and net levels.

At a current price of $23.73, CATALYST PHARMACEUTICALS, INC. appears undervalued relative to its fundamentals. Our value factor score of 85/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The stock screens as attractively priced on a majority of these measures, suggesting the market may be underappreciating the underlying fundamentals.

The stock currently trades at a P/E of 14.5x (a 35% discount to the sector median of 22.3x), EV/EBITDA of 12.1x (near the sector median), P/B of 3.3x, P/S of 5.3x. The below-sector P/E suggests possible undervaluation or the market pricing in near-term headwinds.

We assign a Low uncertainty rating to CATALYST PHARMACEUTICALS, INC.. The company exhibits strong financial stability with a beta of 0.80, conservative leverage (14% D/E), and a stability factor in the 82th percentile. The predictable nature of the business model and solid financial position reduce the range of potential outcomes, giving us confidence in our fair value estimate.

We identify no major risk factors at this time. The company's stability factor sits at the 82th percentile with quality at the 79th percentile, both of which support our low-risk assessment. The absence of material leverage, profitability, or volatility concerns reduces the likelihood of a permanent capital loss scenario.

Key risk mitigants include: healthy gross margins of 86% provide a buffer against cost pressures; conservative leverage (14% D/E) limits balance sheet risk; above-average stability (82th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.

We rate CATALYST PHARMACEUTICALS, INC.'s capital allocation as Exemplary. Management demonstrates a strong track record of balancing reinvestment with shareholder returns, evidenced by returns on equity of 22.3%, disciplined leverage (14% D/E), best-in-class net margins of 36.3%. Exemplary allocators typically generate returns on equity above 20% while maintaining debt-to-equity below 50% — CATALYST PHARMACEUTICALS, INC. meets this high bar.

The balance sheet remains conservatively managed, providing financial flexibility for opportunistic investments while maintaining a margin of safety for shareholders. We note that the combination of 19.5% return on assets and controlled leverage suggests management is deploying capital at rates well above the cost of capital — the hallmark of exemplary stewardship.

In summary, CATALYST PHARMACEUTICALS, INC. receives a Hold rating with a composite score of 63.5/100 (rank #387 of 7,333). Our quantitative framework assigns a Narrow Moat (55/100, trend: widening), Low uncertainty, and Exemplary capital allocation. The average factor score across quality, value, momentum, stability, and investment is 67/100.

Our analysis supports a neutral stance on CATALYST PHARMACEUTICALS, INC.. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.